Shots:

• The companies will jointly develop- manufacture & commercialize Vir's Ab. WuXi Biologics will conduct cell-line development- process & formulation development and initial manufacturing for clinical development
• Following the regulatory approvals- Wuxi Biologics to get rights to commercialize therapies in Greater China while Vir retain WW commercial rights for the therapies
• The collaboration accelerates the advancement of mAb against the global threat of COVID-19. Vir’s platform is used to identify rare Abs from survivor- treating rapidly evolving or previously untreatable pathogens via direct pathogen neutralization and immune system stimulation

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Wuxi Biologics